Yakun Li

Ms. Yakun Li


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
Isabel KrugIsabel Krug
Isabel Krug
ADAn Binh Dang
An Binh Dang
JPJade Portingale
Jade Portingale
YLYakun Li
Yakun Li
YWYing Qing Won
Ying Qing Won
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed treatment for higher weight and diabetes. Because they also influence appetite and reward processes, these medications may shape eating behaviours, emotions, and body image, raising new challenges for eating disorder (ED) research and clinical care. This narrative review synthesises emerging evidence on the psychological and behavioural effects of GLP-1RA use within a biopsychosocial and equity framework. Method: Using a narrative, non-systematic approach, we conducted targeted searches across major databases (2015–September 2025) with combined GLP-1RA and psychological or ED-related terms, supplemented by cross-referencing. Inclusion criteria focused on empirical, theoretical, and clinically meaningful psychological, behavioural, and sociocultural outcomes, enabling a conceptually driven synthesis of the psychological effects of GLP-1RA use. Results: GLP-1RAs reduce hunger and binge-eating frequency, suggesting possible benefits for binge-type EDs. However, evidence for restrictive EDs remains limited, and appetite suppression may reinforce rigid control or perfectionistic traits. Although short-term reductions in emotional eating have been reported, the long-term psychological safety of GLP-1RAs is unknown. Rapid, medication-driven weight loss may disrupt body perception, while social media discourse glamorises thinness and intensifies stigma. These psychosocial effects intersect with inequities in access, disproportionately affecting adolescents and individuals from culturally diverse or socioeconomically marginalised groups. Conclusions: GLP-1RAs sit at the intersection of medical innovation and psychological risk. To ensure safe and inclusive use, research and clinical practice should integrate developmental, cultural, and lived-experience perspectives. Co-designed research and multidisciplinary monitoring will be essential to reduce stigma, address inequities, and support psychologically informed care.

10 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Isabel KrugIsabel Krug
Isabel Krug
ADAn Binh Dang
An Binh Dang
JPJade Portingale
Jade Portingale
YLYakun Li
Yakun Li
YWYing Qing Won
Ying Qing Won
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionised higher weight and diabetes treatment, but their effects on appetite and reward also intersect with eating, emotional, and body image processes, posing new challenges for eating disorder (ED) re-search and care. This narrative review integrates emerging evidence on how GLP-1RA usage shapes eating behaviours, emotional functioning, and body image within a biopsychosocial and equity framework. Method: Using a narrative, non-systematic approach, recent empirical, theoretical, and clinical literature on GLP-1RA use and its psychological and behavioural effects was thematically synthesised across biological, psycho-logical, and sociocultural domains. Results: GLP-1RAs reduce hunger and binge-eating frequency, indicating potential benefit for binge-type EDs (e.g. bulimia nervosa, binge-eating dis-order). However, evidence for restrictive EDs remains limited, and appetite suppression may reinforce rigid control or perfectionistic tendencies. Alt-hough short-term reductions in emotional eating have been reported, the long-term psychological and mental health safety of GLP-1RA use is unclear. Moreover, rapid, pharmacologically driven weight loss can destabilise body perception, while pervasive social media portrayals of GLP-1RA usage fre-quently glamorise thinness and perpetuate weight stigma. These psychoso-cial dynamics intersect with broader structural inequities—such as disparities in healthcare access and affordability—that disproportionately affect special populations (adolescents and those from culturally/ethnically diverse or so-cioeconomically disadvantaged backgrounds), for whom research remains scarce. Conclusions: GLP-1RA use sits at the intersection of metabolic innova-tion and psychological vulnerability. Integrating developmental, cultural, and lived-experience perspectives through co-designed research and multi-disciplinary clinical monitoring will be essential to mitigate stigma, address inequities, and ensure safe, inclusive, and psychologically informed GLP-1RA usage.